Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Annemie Buelens"'
Autor:
Annemie Buelens, Bart Fevery, James Witek, Erkki Lathouwers, Yves Wyckmans, Anne Ghys, Oliver Lenz, Alessandra Baldini, Christoph Sarrazin, Monika Peeters, M. Schlag, Bjorn Daems, Thierry Verbinnen, Sandra De Meyer
Publikováno v:
Antiviral Research. 116:10-16
Hepatitis C virus (HCV) NS3 polymorphism Q80K is mainly found in patients with HCV genotype (G) 1a, and has been associated with a reduced treatment response to simeprevir with pegylated interferon (P) and ribavirin (R). Prevalence of Q80K among G1 p
Autor:
Herta Crauwels, Rolf P. G. van Heeswijk, Marita Stevens, Richard M. W. Hoetelmans, Annemie Buelens
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 52:118-128
Rilpivirine is a human immunodeficiency virus Type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor. Objective: Rilpivirine metabolism involves cytochrome P450 3A4 (CYP3A4). This trial (ClinicalTrials. gov number: NCT00739622) evaluated the i
Autor:
Annemie Buelens, Herta Crauwels, Richard M. W. Hoetelmans, Rolf van Heeswijk, Katia Boven, Marita Stevens
Publikováno v:
The Journal of Clinical Pharmacology. 53:834-840
The objective of the study was to determine the impact of food and different meal types on the pharmacokinetics of rilpivirine, a nonnucleoside reverse transcriptase inhibitor. In this open-label, randomized, crossover study, healthy volunteers recei
Autor:
Kim Thys, Veerle Van Eygen, Annemie Buelens, James Witek, Oliver Lenz, Jeroen Aerssens, Sandra De Meyer, Bart Fevery, Elizabeth Van Rossem, Gaston Picchio, Thierry Verbinnen
Publikováno v:
Open Forum Infectious Diseases
Deep sequencing analyses in HCV genotype 1-infected patients treated with simeprevir/peginterferon/ribavirin showed that pre-existing minority HCV variants did not impact treatment outcome and emerging resistant variants in patients failing treatment
Autor:
Herta, Crauwels, Rolf P G, van Heeswijk, Marita, Stevens, Annemie, Buelens, Simon, Vanveggel, Katia, Boven, Richard, Hoetelmans
Publikováno v:
AIDS reviews. 15(2)
Rilpivirine (TMC278) is a non-nucleoside reverse transcriptase inhibitor approved in combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-naive adults (Edurant(®) 25 mg once daily; Complera(®) [USA]/Eviplera(®)
Autor:
Herta M, Crauwels, Rolf P G, van Heeswijk, Ann, Vandevoorde, Annemie, Buelens, Marita, Stevens, Richard M W, Hoetelmans
Publikováno v:
Journal of clinical pharmacology. 54(2)
Antiretrovirals may influence methadone exposure in HIV-1-infected patients receiving methadone for opiate addiction. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor for treating HIV-1 infection. In this open-label trial (NCT00744770)
Autor:
Herta M, Crauwels, Rolf P G, van Heeswijk, Annemie, Buelens, Marita, Stevens, Katia, Boven, Richard M W, Hoetelmans
Publikováno v:
Journal of clinical pharmacology. 53(8)
The objective of the study was to determine the impact of food and different meal types on the pharmacokinetics of rilpivirine, a nonnucleoside reverse transcriptase inhibitor. In this open-label, randomized, crossover study, healthy volunteers recei
Autor:
Lotke Tambuyzer, Thierry Verbinnen, G. Picchio, Monika Peeters, Annemie Buelens, L. Vijgen, Bart Fevery, M. Beumont-Mauviel, S. De Meyer, Oliver Lenz
Publikováno v:
Journal of Hepatology. 60:S139-S140
Autor:
Oliver Lenz, Sandra De Meyer, Gaston Picchio, Leen Vijgen, Maria Beumont, Bart Fevery, Hugo Ceulemans, Thierry Verbinnen, Monika Peeters, Lotke Tambuyzer, Annemie Buelens
Publikováno v:
Journal of Hepatology. (5):1008-1014
Background & Aims Simeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of chronic HCV infection. Baseline NS3 polymorphisms in all patients and emerging mutations in patients who failed to achieve sustained v